Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

The ruxolitinib cream met its primary end point as a treatment for prurigo nodularis in one phase 3 trial but fell short in ...

This growth comes on the back of a steady market performance from 2017 to 2022, where the injection pen sector achieved a ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Dupixent made about €13 billion in its first full year, while Beyfortus, a novel RSV vaccination for babies, became a bestseller with €1.7 billion. SNY’s EPS grew 4.1% at CER to €7.12 ...

Linvoseltamab is administered with an initial step-up dosing regimen followed by the full 200 mg dose administered weekly. At week 16, all patients transition to every two-week dosing. A ...

Regeneron Pharmaceuticals has built its success on a foundation of innovative drug development, with key products including Eylea for eye diseases and Dupixent for various inflammatory conditions. The ...

Bernstein reduced its price target to $1,000, retaining an Outperform rating, following lower-than-expected Dupixent sales and anticipated EPS shortfall. TD Cowen decreased its price target to $1,030, ...

Bernstein reduced its price target to $1,000, retaining an Outperform rating, following lower-than-expected Dupixent sales and anticipated EPS shortfall. TD Cowen decreased its price target to $ ...

They include Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's own IL-5 inhibitor Fasenra (benralizumab), which competes with GlaxoSmithKline's Nucala (mepolizumab) and Teva's ...

With a portfolio of approved therapies, including EYLEA, Dupixent, and Libtayo, and a robust pipeline targeting eye diseases, inflammatory conditions, cancer, and rare diseases, it’s advancing ...